Gene · 4919
Papers2,258
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 2,258
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| From the archives of MD Anderson Cancer Center: Sporadic Burkitt lymphoma with a complex karyotype and SOX11 expression. | Ann Diagn Pathol | 2023 | 37543028 | PubTator, text mining | PubMed |
| Cortactin contributes to the tumorigenesis of gastric cancer by activating ERK/MMP pathway. | Heliyon | 2023 | 37539204 | PubTator, text mining | PubMed |
| Ehrlichia Wnt SLiM ligand mimic deactivates the Hippo pathway to engage the anti-apoptotic Yap-GLUT1-BCL-xL axis. | Infect Immun | 2023 | 37530530 | PubTator, text mining | PubMed |
| Extracellular vesicles in COVID-19 convalescence can regulate T cell metabolism and function. | iScience | 2023 | 37520724 | PubTator, text mining | PubMed |
| Senescence-Driven Inflammatory and Trophic Microenvironment Imprints Mesenchymal Stromal/Stem Cells in Osteoarthritic Patients. | Biomedicines | 2023 | 37509633 | PubTator, text mining | PubMed |
| Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy. | Cancers (Basel) | 2023 | 37509394 | PubTator, text mining | PubMed |
| Liquid Biopsy in Neurological Diseases. | Cells | 2023 | 37508574 | PubTator, text mining | PubMed |
| Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies. | Cells | 2023 | 37508523 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review. | Curr Oncol | 2023 | 37504334 | PubTator, text mining | PubMed |
| Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer. | Int Immunopharmacol | 2023 | 37499397 | PubTator, text mining | PubMed |
| Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications. | Front Cell Dev Biol | 2023 | 37492224 | PubTator, text mining | PubMed |
| Sequence variants contributing to dysregulated inflammatory responses across keratoconic cone surface in adolescent patients with keratoconus. | Front Immunol | 2023 | 37483635 | PubTator, text mining | PubMed |
| B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers. | Front Oncol | 2023 | 37483496 | PubTator, text mining | PubMed |
| Evaluation of the prognostic significance of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in lung carcinoma and its relation to lymphangiogenesis and epithelial mesenchymal transition. | Pathol Res Pract | 2023 | 37481855 | PubTator, text mining | PubMed |
| CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics. | Front Mol Biosci | 2023 | 37469704 | PubTator, text mining | PubMed |
| In silico analysis reveals mir-98-5p as a potential inhibitor of tumor cell proliferation and metastasis in colorectal cancer by targeting the fzd3 receptor of the Wnt signaling pathway. | J Genet Eng Biotechnol | 2023 | 37466730 | PubTator, text mining | PubMed |
| T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions. | Front Oncol | 2023 | 37465110 | PubTator, text mining | PubMed |
| Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer. | Front Cell Dev Biol | 2023 | 37457288 | PubTator, text mining | PubMed |
| European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of In Situ Hybridization Techniques for Drug Research and Development. | Toxicol Pathol | 2023 | 37449403 | PubTator, text mining | PubMed |
| Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches. | Int J Mol Sci | 2023 | 37445860 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4919/papers?page=17